Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
3期
进行中（已停止招募）
NCT02842086
| 适应症 | Pre-Exposure Prophylaxis of HIV-1 Infection |
|---|
| 分期 | 3期 |
|---|
| 申办方 | Gilead Sciences |
|---|
| 状态 | 进行中（已停止招募） |
|---|
| 受试者人数 | 5,399 人 |
|---|
| 干预（药物） | F/TAF, F/TDF, F/TAF Placebo, F/TDF Placebo |
|---|
| 开始日期 | 2016年9月2日 |
|---|
| 完成日期 | 2019年1月31日 |
|---|
| 结果公布日 | 2020年3月17日 |
|---|
摘要
The primary objective of this study is to assess the rates of HIV-1 infection in Men (MSM) and transgender women (TGW) who have sex with men and who are administered daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) with a minimum follow-up of 48 weeks and at least 50% of participants have 96 weeks of follow-up after randomization.
Incidence of HIV-1 Infection Per 100 Person Years (PY)
When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks) · HIV-1 infections per 100 PY
| Descovy (DVY) | 0.160 HIV-1 infections per 100 PY |
|---|
| Truvada (TVD) | 0.342 HIV-1 infections per 100 PY |
|---|
| Rate Ratio | 0.468 (95% CI 0.191–1.149) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。